Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 12/2001

01-10-2001 | Leading Article

Hepatotoxicity with Thiazolidinediones

Is it a Class Effect?

Author: Dr André J. Scheen

Published in: Drug Safety | Issue 12/2001

Login to get access

Abstract

Decreased insulin sensitivity plays a major role in various human diseases, particularly type 2 diabetes mellitus, and is associated with a higher risk of atherosclerosis and cardiovascular complications. Thiazolidinediones, more commonly termed glitazones, are the first drugs to specifically target muscular insulin resistance. They have proven efficacy for reducing plasma glucose levels in patients with type 2 diabetes mellitus treated with diet alone, sulphonylureas, metformin or insulin. In addition, they are associated with some improvement of the cardiovascular risk profile. However, troglitazone, the first compound approved by the Food and Drug Administration in the US, proved to be hepatotoxic and was withdrawn from the market after the report of several dozen deaths or cases of severe hepatic failure requiring liver transplantation.
It remains unclear whether or not hepatotoxicity is a class effect or is related to unique properties of troglitazone. Rosiglitazone and pioglitazone, two other glitazones, appear to have similar efficacy with regard to blood glucose control in patients with type 2 diabetes mellitus as compared with troglitazone. In controlled clinical trials, the incidence of significant (≥3 × upper limit of normal) increases in liver enzyme levels (ALT in particular) was similar with rosiglitazone or pioglitazone as compared with placebo, whereas troglitazone was associated with a 3-fold greater incidence. In contrast to the numerous case reports of acute liver failure in patients receiving troglitzone, only a few case reports of hepatotoxicity have been reported in patients treated with rosiglitazone until now, with a causal relationship remaining uncertain. Furthermore, no single case of severe hepatotoxicity has been reported yet with pioglitazone. It should be mentioned that troglitazone, unlike pioglitazone and rosiglitazone, induces the cytochrome P450 isoform 3A4, which is partly responsible for its metabolism, and may be prone to drug interactions. Importantly enough, obesity, insulin resistance and type 2 diabetes mellitus are associated with liver abnormalities, especially non-alcoholic steatohepatitis, independent of any pharmacological treatment. This association obviously complicates the selection of patients who are good candidates for a treatment with glitazones as well as the monitoring of liver tests after initiation of therapy with any thiazolidinedione compound. While regular monitoring of liver enzymes is still recommended and more long term data are desirable, current evidence from clinical trials and postmarketing experience in the US supports the conclusion that rosiglitazone and pioglitazone do not share the hepatotoxic profile of troglitazone.
Literature
1.
Scheen AJ, Lefèbvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of Experimental Pharmacology, Oral Antidiabtics. Springer Verlag: Berlin, 1996: 7–42
2.
Chen Y-DI, Reaven GM. Insulin resistance and atherosclerosis. Diabetes Rev 1997; 5(4): 331–42
3.
Scheen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev 1999; 7(2): 77-93
4.
Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997 Sep; 54(3): 355–68PubMedCrossRef
5.
Gilbert RE, Cooper ME, Krum H. Drug administration in patients with diabetes mellitus. Safety considerations. Drug Saf 1998 Jun; 18(6): 441–55PubMedCrossRef
6.
Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996 Dec; 45(12): 1661–9PubMedCrossRef
7.
Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Exp Opin Invest Drugs 1997; 6: 1025–40CrossRef
8.
9.
Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diab Med 1999 Mar; 16(3): 179–92CrossRef
10.
Scheen AJ, Paquot N, Letiexhe MR, et al. Les thiazolidinediones. In: Journées de diabétologie de l’Hôtel-Dieu, Flammarion. Paris: Médecine-Sciences, 1999: 213–29
11.
12.
13.
Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998 Feb; 55(2): 225–36PubMedCrossRef
14.
Campbell IW. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 2000 Nov; 60(5): 1017–28PubMedCrossRef
15.
Spiegelman BM. PPAR-g adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–14PubMedCrossRef
16.
17.
Chen C. Troglitazone: an antidiabetic agent. Am J Health Syst Pharm 1998 May; 55(9): 905–25PubMed
18.
Johnson MD, Campbell LK, Campbell RK. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother 1998 Mar; 32(3): 337–48PubMedCrossRef
19.
Plosker GL, Faulds D. Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 1999 Mar; 57(3): 409–38PubMedCrossRef
20.
Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone [letter]. N Engl J Med 1998 Mar; 338(13): 916–7PubMedCrossRef
21.
Kohlroser J, Mathai J, Reichheld J, et al. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000 Jan; 95(1): 272–6PubMedCrossRef
22.
23.
24.
Bailey CJ. Rosiglitazone and pioglitazone: two new thiazolidinediones. Pract Diab Int 2000 Jul/Aug; 17(5): 135–7CrossRef
25.
Bankhead C. Not all glitazone tarnished by hepatotoxicity. Inpharma 2000 Aug; 1249: 19–20CrossRef
26.
Van Gaal L, Scheen AJ, editors. Are all glitazones the same? Satellite symposium of the EASD 1999. Diabetes/Metab Rev Res, 2001 (Suppl.). In press
27.
Daniel K. The glitazones: proceed with caution. West J Med; 2000 Jul; 173(1): 54–7CrossRef
28.
Tolman KG. Thiazolidinedione hepatotoxicity: a class effect? IJCP 2000 Oct; Suppl. 113: 29–34
29.
Petrides AS. Liver disease and diabetes mellitus. Diabetes Rev 1994; 2: 2–18
30.
Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137–45PubMed
31.
Ludwig J, McGill DB, Lindor KD. Review: Non alcoholic steatohepatitis. J Gastroenterol Hepatol 1997; 12: 398–403PubMedCrossRef
32.
James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495–501PubMedCrossRef
33.
34.
Luyckx FH, Lefèbvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diab Metab 2000; 26: 98–106
35.
Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970; 3: 371–407PubMed
36.
37.
Salmela PI, Sotaniemi EA, Niem M, et al. Liver function tests in diabetic patients. Diabetes Care 1984; 7: 248–54PubMedCrossRef
38.
Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 2000 Nov; 109(7): 588–90PubMedCrossRef
39.
Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obesity 1995; 19Suppl. 3: S27–36
40.
Zimmerman HJ, MacMurray FG, Rappaport H, et al. Studies of the liver in diabetes mellitus II. The significance of fatty metamorphosis and its correlation with insulin insensitivity. J Lab Clin Med 1950; 36: 922–7PubMed
41.
Nagore N, Scheuer PJ. The pathology of diabetic hepatitis. J Pathol 1998; 156: 155–60CrossRef
42.
Wanless IR, Lentz JS. Fatty liver steatosis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106–0PubMedCrossRef
43.
Silverman JF, O’Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349–55PubMed
44.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9PubMedCrossRef
45.
Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C infection. Hepatology 1999; 29: 328–3PubMedCrossRef
46.
Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000 Oct; 133(8): 592–9PubMed
47.
Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999 Dec; 22(12): 2067–71PubMedCrossRef
48.
Dossing M, Sonne J. Drug-induced hepatic disorders: incidence, management and avoidance. Drug Safety 1993; 9: 441–9PubMedCrossRef
49.
50.
Benicho C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272–6CrossRef
51.
Meyboom RH, Hekster YA, Egberts AC, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Safety 1997; 17: 374–89PubMedCrossRef
52.
Michalets EL. Update: clinically significant cytochrome P 450 drug intercations. Pharmacotherapy 1998; 18: 84–112PubMed
53.
Yamazaki H, Suzuki M, Tane K, et al. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 2000 Jan; 30(1): 61–70PubMedCrossRef
54.
Scheen AJ, Lefèbvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999 Sep; 22(9): 1568–77PubMedCrossRef
55.
56.
Wageaar LJ, Kuck EM, Hoekstra JB. Troglitazone. Is it all over? Neth J Med 1999 Jul; 55(1): 4–12CrossRef
57.
58.
Liver damage warnings for troglitazone. Scrip 1997 Nov; 7 (2282): 21
59.
Call to ban troglitazone in US. Scrip 1998 Jul; 31 (2357): 22
60.
61.
Food and Drug Administration. FDA Talk paper. Washington, DC: US Department of Health and Human Services; March 21, 2000
62.
Gitlin N. Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998 Jul; 129(1): 36–8PubMed
63.
Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 1998 Jul; 129(1): 38–41PubMed
64.
Shibuya A, Watanabe M, Fujita Y, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998 Dec; 21(12): 2140–3PubMedCrossRef
65.
Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone [letter]. Ann Intern Med 1998 Dec; 129(12): 1080PubMed
66.
Neuschwander-Tetri BA, Isley WL, Oki JC. Troglitazone-associated hepatic failure [letter]. Ann Intern Med 1999 Feb; 130(4): 330
67.
Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone [letter]. Ann Intern Med 1999 Jan; 130(2): 163PubMed
68.
Misbin RI. Troglitazone-associated hepatic failure [letter]. Ann Intern Med 1999 Feb; 130(4): 330PubMed
69.
Iwase M, Yamaguchi M, Yoshinari M, et al. A Japanese case of liver dysfunction after 19 months of troglitazone treatment [letter]. Diabetes Care 1999 Aug; 22(8): 1382–4PubMedCrossRef
70.
Jogannath S, Rai R. Rapid-onset subfulminant liver failure associated with troglitazone [letter]. Ann Intern Med 2000 Apr; 132(8): 677
71.
Fukano M, Amano S, Sato J, et al. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum Pathol 2000 Feb; 31(2): 250–3PubMedCrossRef
72.
Malik AH, Prasad P, Saboorian MH, et al. Hepatic injury due to troglitazone. Dig Dis Sci 2000 Jan; 45(1): 210–4PubMedCrossRef
73.
Murphy EJ, Davern TJ, Shakil AO, et al. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci 2000 Mar; 45(3): 549–3PubMedCrossRef
74.
Schiano T, Dolehide K, Hart J, Baker AL. Severe but reversible hepatitis induced by troglitazone. Dig Dis Sci 2000 MAy; 45(5): 1039–42PubMedCrossRef
75.
Booth AM, Caldwell SH, Iezzoni JC. Troglitazone-associated hepatic failure. Am J Gastroenterol 2000 Feb; 95(2): 557–8PubMed
76.
Prendergast KA, Berg CL, Wisniewski R. Troglitazone-associated hepatotoxicity treated successfully with steroids [letter]. Ann Intern Med 2000 Nov; 133(9) 751PubMed
77.
Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000 Aug; 133(4): 263–74PubMed
78.
Kuramoto K, Shimizu N, Toda G. Liver dysfunction associated with troglitazone (Noscal) [in Japanese]. Rinsho Iyaku 1998; 14: 461–6
79.
Ogata E, Yamada Y, Iga R. Liver dysfunction due to troglitazone [in Japanese]. Naika 1999; 83: 534–9
80.
Toyota T, Ueno Y. Clinical effect and side effect of troglitazone [in Japanese]. Nippon Rinsho 2000 Feb; 58(2): 376–82PubMed
81.
82.
Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern [editorial]. N Engl J Med 1998 Mar; 338(13): 908–9PubMedCrossRef
83.
Graham DJ, Drinkard CR, Shati D, Tson Y, Burgess MJ. Liver enzyme monitoring in patient treated with troglitazone. JAMA 2001 Aug; 286: 831–3PubMedCrossRef
84.
Zimmerman HJ, Ishak KG. Hepatic injury due to drugs and toxins. In: MacSween RNM, Anthony PP, Scheuer PJ, et al. editors. Pathology of the liver. 3rd ed. London: Churchill Livingstone, 1994: 563–633
85.
Loi CM, Alvey CW, Randinitis EJ, et al. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 1997; 37: 1038–47PubMed
86.
Loi C-M, Young M, Randinitis E, et al. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999 Aug; 37: 91–104PubMedCrossRef
87.
Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. Eur J Clin Pharmacol 1998 Sep; 54(7): 567–71PubMedCrossRef
88.
Young MA, Lettis S, Eastmond R. Co-administration of acetaminophen and troglitazone: Pharmacokinetics and safety. J Clin Pharmacol 1998; 38(Suppl. 9): 819–25PubMed
89.
Izumi I, Hosiyama K, Enomoto S, et al. Pharmacokinetics of troglitazone, an antidiabetic agent: Prediction of in vivo stereo-selective sulphation and glucuronidation from in vitro data. J Pharmacol Exptl Therap 1997 Mar; 280(3): 1392–400
90.
Kawai K, Kawasaki-Tokui Y, Odaka T, et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittel-Forschung 1997 Apr; 47(4): 356–68PubMed
91.
Yamazaki H, Shibata A, Suzuki M, et al. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 1999; 27: 1260–6PubMed
92.
Ramachandran V, Kostrubsky VE, Komoroski BJ, et al. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab Disp 1999 Oct; 27(10): 1194–9
93.
Sahi J, Hamilton G, Sin M et al. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 2000 Mar; 30: 273–84PubMedCrossRef
94.
Peter JV, Neafus KL, Khan MA, et al. Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione. Pharmacotherapy 2001 Feb; 21: 183–8CrossRef
95.
Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001 Apr; 33: 1009–13PubMedCrossRef
96.
Inoue I, Katayama S, Takahashi K, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Comm 1997; 235: 113–6PubMedCrossRef
97.
Kassahun K, Pearson PG, Tan W et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 2001 Jan; 14: 62–70PubMedCrossRef
98.
Guillouzo A, Morel F, Langouet S, et al. Use of hepatocyte cultures for the study of hepatotoxicity compounds. Toxicology 1997; 82(Suppl. 1-3): 209–19
99.
Kostrubsky VE, Sinclair JF, Ramachandran V, et al. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Disp 2000 Oct; 28(10): 1192–7
100.
Elcock FJ, Lyon JJ, Hitchcock J, et al. Toxicity of troglitazone in cultured rat hepatocytes [abstract]. Diabetes 1999; 48Suppl. 1: A63
101.
Funk C, Ponelle C, Scheuermann G, et al. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001 Mar; 59: 627–35PubMed
102.
Galli EL, Crabb D. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 2000 Jun; 20(3): 191–9PubMedCrossRef
103.
Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrinogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000 Aug; 119(2): 466–78PubMedCrossRef
104.
Jia DM, Tabaru A, Akiyama T, et al. Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol 2000 Oct; 15(10): 1183–91PubMedCrossRef
105.
Scheen AJ. Thiazolidinediones and liver toxicity. Diab Metab 2001; 27: 305–13
106.
Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001 Feb; 96: 519–25PubMedCrossRef
107.
Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001 Jun; 357:1870-5
108.
Goldstein BJ. Rosiglitazone. Int J Clin Pract 2000 Jun; 54(5): 333–7PubMed
109.
Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22(10): 1151–68PubMedCrossRef
110.
Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week randomized, placebo controlled study. Diabetes Obesity Metab 1999; 1: 165–72CrossRef
111.
Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone shortterm monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000 Mar; 43(3): 278–84PubMedCrossRef
112.
Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet Med 2000 Apr; 17(4): 287–94PubMedCrossRef
113.
Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000 Jan; 17(1): 40–7PubMedCrossRef
114.
Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 2000 Apr; 283(13): 1695–702PubMedCrossRef
115.
Salzman A, Patel J. Rosiglitazone is not associated with hepatotoxicity [abstract]. Diabetes 1999; 48Suppl. 1: A95
116.
Lebovitz HE, Salzman A. Rosiglitazone liver safety update [abstract]. Diabetes 2000; 49Suppl. 1: A39
117.
Buckingham RE, Birmingam J, O’Brien P, et al. Rapid reversal of hepatic steatosis by rosiglitazone [abstract]. Diabetologia 2001 Sep; 44Suppl. 1: A200
118.
Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000 Jan; 132(2): 118–21PubMed
119.
AI-Salman J, Arjomand H, Kemp D, et al. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 2000 Jan; 132(2): 121–4
120.
Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure [letter]. Ann Intern Med 2000 Jan; 132(2): 164PubMed
121.
Isley WL, Oki JC. Rosiglitazone and liver failure. Ann Intern Med 2000 Sep; 133(5): 393–4PubMed
122.
Ravinuthala RS, Nori U. Rosiglitazone toxicity [letter]. Ann Intern Med 2000 Oct; 133: 658PubMed
123.
Canada reports 166 ADRs with Avandia. Scrip 2001 Aug; 2668: 23
124.
Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28(7): 772–80PubMed
125.
Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999 Sep; 48(3): 424–32PubMedCrossRef
126.
Thompson KA, Miller AK, Inglis AML, et al. Rosiglitazone does not markedly alter CYP3A4-mediated drug metabolism [abstract]. Diabetologia 1999; 42Suppl. 1: A227
127.
Klotz U, Sailer D. Arzneimittelinteraktionen - ihre Bedeutung für eine sichere Therapie am Beispiel der neuen Wirkstoffgruppe der Thiazolidindione (Glitazone). Arzneim-Forsch/Drug Res 2001 Jan; 51: 112–7
128.
Miller AK, Inglis AL, Thompson K, et al. Effect of hepatic impairment on the pharmacokinetics of rosiglitazone [abstract]. Clin Pharmacol Ther 1999; 65: PIII–37CrossRef
129.
New drug overview. Pioglitazone hydrochloride. Am J Health Syst Pharm 2000; 57: 124–5
130.
Aronoff S, Rosenblatt S, Braithwaite S, et al. for The Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000 Nov; 23(11): 1605–1PubMedCrossRef
131.
Einhorn D, Rendell M, Rosenzweig J, et al. for The Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study Clin Ther 2000; 22: 1395–409PubMedCrossRef
132.
Rubin C, Schneider R. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials [abstract]. Diabetes 2000; 49Suppl. 1: A123
133.
Belcher G, Matthews DR. Safety and tolerability of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108Suppl. 2: S267–73CrossRef
134.
Weinstock RS, Murray FT, Diani A, et al. Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. Pharmacology 1997 Apr; 54(4): 169–78PubMedCrossRef
135.
Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108Suppl. 2: S234–42CrossRef
136.
Glazer NB, Cheatham WW. Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4 [letter]. BMJ 2001 Jan; 322: 235–6PubMedCrossRef
137.
Aoyama E, Tsujiuchi H, Asahi S, Yamashita K, Yoshimura Y. In vitro studies on the metabolic pathways of pioglitazone [abstract]. Diabetes 2001 Jun; 50(Suppl 1): A105
138.
Kortboyer JM, Eckland D. Pioglitazone has low potential for drug interactions [abstract]. Diabetologia 1999 Aug; 42Suppl. 1: A228
Metadata
Title
Hepatotoxicity with Thiazolidinediones
Is it a Class Effect?
Author
Dr André J. Scheen
Publication date
01-10-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 12/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124120-00002

Other articles of this Issue 12/2001

Drug Safety 12/2001 Go to the issue

Leading Article

Post-Marketing Surveillance and Vigilance for Medical Devices

Original Research Article

Long Term Follow-Up Studies of Users of Nonprescription Medicines Purchased from Community Pharmacies

Review Article

Medication Overuse Headache

Review Article

A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form

Review Article

Drug—Induced Congenital Defects